anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An implantable multiple-agent biologic delivery system includes a pod (10) proportioned for subcutaneous implantation beneath the dermis (22) of the skin, the pod (10) including a porous surface (14) and having at least one internal chamber (16) which is in fluid communication with the porous surface (14). The system includes a dome (26) proportioned for selectable detachable securement to the chamber of the pod (10). The dome (26) includes interior chambers (32), each in fluid communication with the interior of the pod (10). Bio-acting agents, such as hormones, enzymes, biologic response modifiers, free radical scavengers, and genetically altered cell cultures, may be provided, within the chambers (32) of the dome, prior to implantation. Such agents within the dome will, through the use of time release micropumps, enter the interior of the pod for transmission through the porous surfaces into a vascular growth factor stimulated capillary matrix and then to the bloodstream of the user. The pod may be removed, refilled, and resecured to the dome upon exhaustion of its contents or upon medical requirement for changes in medication, or may be percutaneously refilled in situ through injection into the dome.
Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, only one quarter of the normal amount of anticoagulation is administered.
To explore the clinical and pathological characteristics as well as therapies and prognosis of gray zone lymphoma (GZL). The clinical data of 10 GZL patients admitted to the First Affiliated Hospital of Soochow University from December 2016 to December 2022 were retrospectively collected. The clinical and pathological characteristics, therapies and prognosis were analyzed. The cut-off time for follow-up visits was December 31, 2022, and the median time for follow-up visits [M(Q1, Q3)] was 40.0 (28.3, 59.8) months. Treatment efficacy was divided into complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD). There were 6 males and 4 females, with a median age [M(Q1, Q3)] of 33.5 (27.3-39.5) years. Among them, 8 patients had mediastinal (thymus) involvement and 7 patients were accompanied with extranodal involvement. According to Ann Arbor staging, 1 case was in the limited stage and 9 cases were in the progressive stage. The immunophenotypes of 4 patients were strong expression of CD20, expression of CD30, and no expression of CD15. The immunophenotypes of 6 patients were unequal expression of CD20 and strong expression of CD30 and CD15. One patient received classical hodgkin lymphoma(cHL)-like immunochemotherapy and only achieved PR, and then received enhanced diffuse large b-cell lymphoma (DLBCL)-like immunochemotherapy to achieve CR. Five patients received enhanced DLBCL-like immunochemotherapy for induction therapy and achieved CR. All 4 patients who did not achieve CR achieved CR after receiving second-line or third-line salvage therapy. All patients were given autologous stem cell transplantation (ASCT) for consolidation therapy. One patient relapsed and died during the follow-up visit in the 33rd month, and the remaining patients currently maintained a state of sustained remission. It is found that GZL mostly occurs in young patients, mediastinal involvement is common, and diagnosis relies on pathological morphology and immunophenotype. GZL may be more sensitive to DLBCL-like intensive immune regimens. Sequential ASCT for consolidation can reduce the risk of relapse.
Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
BACKGROUND: Sex differences in obesity and fat distribution may in part explain differences in cardiovascular risk in men versus women. We sought to examine sex differences in the associations of obesity and adiposity measures with cardiovascular disease-related protein biomarkers.
METHODS AND RESULTS: In a cross-sectional observational cohort study, we examined whether the association of obesity (body mass index [BMI] and waist circumference) and adiposity measures (visceral adipose tissue) with biomarkers demonstrates effect modification by sex using multiplicative interaction terms in multivariable linear regression models. Among 3143 participants (mean age, 50 years; 49% women), sex modified the association of BMI, waist circumference, and visceral adipose tissue with cardiovascular disease-related protein biomarkers (7 for BMI, 3 for waist circumference, and 23 for visceral adipose tissue, false discovery rate [FDR]-qint<0.05 for all). For example, higher BMI was associated with lower α1-microglobulin levels in men but not in women (ß, -0.113; SE, 0.028; P<0.001 in men versus ß, -0.007; SE, 0.024; P=0.78 in women). By contrast, higher BMI was associated with higher adipsin levels in men and women, but the association was more pronounced in women (ß, 0.287; SE, 0.023; P<0.001 in women versus ß, 0.189; SE, 0.026; P<0.001 in men). The associations of higher visceral adipose tissue with biomarkers representing adiposity, inflammation, and fibrosis were more pronounced in women versus men.
CONCLUSIONS: We found that sex modified the associations of obesity and adipose traits with cardiovascular risk ascertained by cardiovascular disease-related biomarkers including markers of adiposity, inflammation, and fibrosis. These findings highlight potential biological pathways that may underlie some of the observed differences in obesity-related cardiovascular disease between women and men.
Shock is defined as cellular and tissue hypoxia due to either reduced oxygen delivery, increased oxygen consumption, inadequate oxygen utilization, or a combination of these processes. According to the etiology about how it causes a decrease in blood flow to the cells and tissue, there are four types of shock naming cardiogenic shock, hypovolemic shock, obstructive shock, and distributive shock, respectively. The evaluation and management of shock patients is an extremely difficult challenge for the emergency physicians and critical care specialists. How to diagnose, classify, stabilize, and treat the shock patients quickly and in time are the arduous tasks. For the emergency physicians and critical care specialists, how to quickly recognize shock from diverse clinical features and immediately treat shock patients to prevent progression to irreversible organ dysfunction from initially reversible shock condition are important issues and challenges. In recent years, ultrasound instruments have gradually developed with higher radiographic quality and lower cost. Ultrasonography had been extensively used in clinical practice recently, and well-trained medical staffs can quickly and easily apply ultrasound to evaluate, examine, diagnose, and even treat the patients. The clinical application of point-of-care ultrasound can help the firstline physicians rapidly evaluate and diagnose the main symptoms and signs of the patients at bedside, and further initially stabilize and appropriately treat the patients subsequently. The aim of this program is to prospectively collection of the findings of point-of-care ultrasonography in shock patients at emergency room in NTUH. The clinical manifestations, and followed up the examinations, treatments, and prognosis will also be collected. The effect of bedside ultrasound on differential diagnosis and treatment of shock patients will be analyzed. The results of the current study can provide the base for further clinical trials and set up of shock team.
The study will be prospective. Patients who meet entry criteria will be randomized to receive corticosteroids versus placebo. Randomization will take into account biventricular versus univentricular repairs/palliations and whether the patients received intraoperative steroids. Patients will be compared with matched controls based on: diagnosis, +/- intraoperative steroids/phenoxybenzamine, cardiopulmonary bypass/cross clamp/circulatory arrest times and inotrope requirements. Those in the treatment arm will be dosed with hydrocortisone - stress dose (100mg/m2/dose daily x2, then taper with two days at half the original dose and one day at one quarter of the original dose) and then the steroids will be discontinued. Outcome data will include: heart rate, blood pressure, mixed venous oxygen saturation to assess cardiac output, blood cultures/infection/antibiotics (antibiotics as deemed necessary by the primary cardiologist), +/- gastrointestinal bleeding, time to discontinuing inotropic agents, time to extubation, length of intensive care unit admission and survival. Laboratory studies will be assessed before and 24 hours after the institution of steroids. The following labs are standard of care in the unit and will be assessed: glucose, electrolytes, blood urea nitrogen/creatinine, complete blood counts, lactate, arterial blood gases, cultures and stool guaiac. The following labs will be assessed in addition to regular monitoring: cortisol, adrenocorticotropin hormone and C reactive protein.
The invention provides carbamide peroxide, a carbamide peroxide preparation for injection and a preparation method thereof. A method for preparing carbamide peroxide, comprising: mixing raw materials including hydrogen peroxide solution, edetate disodium, citric acid and urea, performing crystallization treatment after reaction, filtering and drying to obtain carbamide peroxide; the dosage of the citric acid is less than or equal to 4% of the mass of the urea. Carbamide peroxide, and is prepared by the preparation method of the carbamide peroxide. A method for preparing a carbamide peroxide preparation for injection comprises the following steps: dissolving the carbamide peroxide in water for injection, filtering, sterilizing and freeze-drying to obtain the carbamide peroxide preparation for injection. The carbamide peroxide preparation for injection is prepared by the preparation method of the carbamide peroxide preparation for injection. The carbamide peroxide and the carbamide peroxide preparation for injection have good long-term stability and high safety.
Potential subjects are female non-smokers presenting to their physicians for treatment of chronic pelvic pain. When consented, the subjects fill out a questionnaire on demographic information and pain experience. The trial is conducted at home over three days. Each subject uses three different levels of nicotine (0mg, 5mg, and 10mg) administered in a random order; the study is double-blinded and patients act as their own controls. Subjects apply the placebo or nicotine patches in the morning and remove them in the evening when they fill out a pain diary for the day. During the study, patients will continue their typical course of pain medication and report pain medication use in the pain diary.
The present invention relates to a composition for skin regeneration, anti-wrinkle, antioxidant and skin whitening effects. According to the present invention, protodioscin promotes collagen generation of fibroblasts and thus has effects of regenerating skin and reducing wrinkles. Protodioscin inhibits generation of free radicals and thus has an anti-oxidant effect. Protodioscin also inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
PROBLEM TO BE SOLVED: To provide a freeze-drying method intended to inhibit a rigid container from breakage in lyophilizing an aqueous liquid agent with an alkali metal (bi)carbonate dissolved therein in the rigid container by adding an alkali (alkaline earth) metal chloride and/or an alkali metal sulfate to the agent. SOLUTION: This freeze-drying method comprises the following procedure: when an aqueous liquid agent with one or more kinds of salt selected from alkali metal carbonates and alkali metal bicarbonates dissolved therein (e.g. an aqueous solution, aqueous suspension or aqueous emulsion of a medicament, pref. 0-200 g of the medicament is included per liter of the aqueous liquid agent) is to be lyophilized in a rigid container (pref. made of glass, mainly used in the form of ampoule, vial, syringe or the like for medicaments), one or more kinds of salts selected from alkali metal chlorides, alkaline earth metal chlorides and alkali metal sulfates is added at pref. 0.001-5 g per g of the total amount of the alkali metal carbonate and/or alkali metal bicarbonate in the aqueous liquid agent.
PCT No. PCT/JP95/00280 Sec. 371 Date Aug. 23, 1996 Sec. 102(e) Date Aug. 23, 1996 PCT Filed Feb. 24, 1995 PCT Pub. No. WO95/23150 PCT Pub. Date Aug. 31, 1995A compound of the formula:    <IMAGE>  [I]  wherein R1 is a hydrogen atom or a lower alkyl group, R2 is a hydrogen atom or a negative charge, R3 is a hydrogen atom or a lower alkyl group, Ar is a phenyl group, a naphthyl group or a group of:  bond, -NHSO2- or the like, and Het is a pyrrolinyl group, a 1,4-diazabicyclo[2.2.2]octanyl group or the like which may be substituted with a hydroxyl group, a carbamoyl lower alkyl group or the like) which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfonyl group or the like; a hydroxyl group; a di-lower alkylsulfamoyl group or the like, each of A1, A2 and A3 is a single bond or a lower alkylene group which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfamoyl group or the like; a pyridyl group or a pyridino group; and W is a sulfur atom, a single bond; or a pharmaceutically acceptable salt or ester; a process for its production and an antibacterial agent containing it as an active ingredient.
Described herein are materials and methods for reducing the risk of infection at a surgical site performed to restore or repair bone in an animal. Bone graft materials for implantation into a mammal are contemplated containing an antimicrobial agent. In one embodiment the bone graft material comprises both calcium phosphate and povidone-iodine as the antimicrobial agent. In another embodiment the bone graft material further comprises collagen. The bone graft materials are designed so as to maintain the structural integrity and/or handling characteristics of the material upon implantation into a bony site. Various methods for manufacturing the bone graft materials described herein are also contemplated.
A CELLULAR VIRAL INHIBITOR COMPOSITION          ABSTRACT         A composition for the treatment and prophylaxis of viral infections in mammals is provided.  The composition includes an amount of a contact-blocking viral inhibitor (CVI) in a diluent sufficient to elevate the concentration of the viral inhibitor in a mammal's tissue above the naturally occurring concentration in that same tissue.  Methods for purifying and concentrating CVI are presented.  The cellular viral inhibitor is characterized by broad antiviral activity, potency, reversible inhibition of viral attachment, cross species activity and molecular size.  Natural levels of CVI range from 6 U/0.1 ml in tears to 400 U/0.1 ml in gastric secretions, with titers between these ranges found in colostrum, milk, plasma, saliva and urine.  Biochemical characterization of the CVI indicates that it resists denaturation by heat, acid and alkali, and it exhibits a molecular size on the order of 2500 daltons.
Acute kidney injury (AKI) is primarily caused by renal ischemia-reperfusion injury (IRI), which is one of the most prevalent triggers. Currently, preventive and therapeutic measures remain limited. Ferroptosis plays a significant role in the pathophysiological process of IRI-induced AKI and is considered a key target for improving its outcomes. Silibinin, a polyphenolic flavonoid, possesses diverse pharmacological properties and is widely used as an effective therapeutic agent for liver diseases. Recent studies have reported that silibinin may improves kidney diseases, though the underlying mechanism remain unclear. In this study, we investigated whether silibinin protects against IRI-induced AKI and explored its mechanism of action. Our findings indicated that pretreatment with silibinin alleviated renal dysfunction, pathological damage, and inflammation in IRI-AKI mice. Furthermore, the results demonstrated that silibinin inhibited ferroptosis both in vivo and in vitro. Proteome microarrays were used to identify silibinin's target, and our results revealed that silibinin binds to FTH1. This binding affinity was confirmed through molecular docking, SPRi, CETSA, and DARTS. Additionally, co-IP assays demonstrated that silibinin disrupted the NCOA4-FTH1 interaction, inhibiting ferritinophagy. Finally, the inhibitory effects of silibinin on ferroptosis were reversed by knocking down FTH1 in vitro. In conclusion, our study shows that silibinin effectively alleviates AKI by targeting FTH1 to reduce ferroptosis, suggesting that silibinin could be developed as a potential therapeutic agent for managing and treating AKI.
PURPOSE: Numerous robot-assisted pancreatic surgery are being performed worldwide. This study aimed to evaluate the feasibility and safety of the Revo-i robot system (Meerecompany, Seoul, Republic of Korea) for advanced pancreatic surgery, and also compare this new system with the existing da Vinci™ robot system (Intuitive Surgical, Sunnyvale, CA, USA) in the context of robot-assisted pancreaticoduodenectomy (RPD).
MATERIALS AND METHODS: This study was a one-armed prospective clinical trial that assessed the Revo-i robot system for advanced pancreatic surgery. Ten patients aged 30 to 73 years were enrolled between December 2019 and August 2020. Postoperative outcomes were retrospectively compared with those of the da Vinci™ surgical system. From March 2017 to August 2020, a total of 47 patients who underwent RPD were analyzed retrospectively.
RESULTS: In the prospective clinical trial, pancreaticoduodenectomy was performed in nine patients and one patient underwent central pancreatectomy. Among the 10 study participants, the incidence of major complications was 0% in hospital stay. There were eight postoperative pancreatic fistula (POPF) biochemical leaks (80%). In the retrospective analysis that compared the Revo-i and da Vinci™ robotic systems, 10 patients underwent Revo-i RPD and 37 patients underwent da Vinci™ RPD, with no significant differences in complication or POPF incidence rates between the two groups (p=0.695, p=0.317).
CONCLUSION: In this single-arm prospective study with short-term follow-up at a single institution, the Revo-i robotic surgical system was safe and effective for advanced pancreatic surgery. Revo-i RPD is comparable to the da Vinci™ RPD and is expected to have wide clinical application.
Compartment syndrome is a condition that occurs when there is an increase in pressure within a muscle compartment, leading to a decrease in blood flow to the muscles and nerves within that compartment. If left untreated, this can lead to ischemic contracture, which is a late sequelae of compartment syndrome that occurs when there is sustained ischemic damage to the muscles. Timely diagnosis and treatment are critical in reducing the extent of permanent changes within muscle and nerve tissue. No previously published studies have reported on the treatment of early ischemic contracture resulting from traumatic haematoma in the upper arm. We present an exceptional case involving a 17-year-old male who developed this condition following a collision during a basketball game, resulting in a haematoma with severe pain, tightness and restricted range of motion in the affected arm. He was treated through surgical intervention involving surgical muscle release, haematoma evacuation and continuous passive motion (CPM) postoperatively to restore the range of motion and improve overall function with complete recovery at the 27-month follow-up.
This study will measure the recovery of participants following Achilles tendon rupture. Measurements will capture individual participants at each rehabilitation time point following Achilles tendon rupture. These time points include following rupture (week 0), after 8 weeks, 10 weeks, 4 months, 6 months and 1 year. The measurements include an ultrasound tissue characterisation scan, isometric (static) strength test and heel raise test. In addition questionnaires will be completed by participants at each time point. Questionnaires include the Achilles Tendon Rupture Score, Hospital Anxiety and Depression Scale, EQ5D (a health related quality of life measure), International Physical Activity Questionnaire, Tampa Scale for Kinesiophobia and the Pain Catastrophising Scale.
BACKGROUND: Emergency general surgery (EGS) is a major part of the provision of healthcare, and patients undergoing EGS are at elevated risk of morbidity and mortality. This study aimed to determine factors contributing to patients losing their independence and being discharged to residential and nursing homes having previously lived in their own residences.
METHODS: Our local data uploaded to the National Emergency Laparotomy Audit (NELA) (2014-2022) were analyzed. This national database encompasses all major EGS cases undertaken in the United Kingdom. The variables considered were patient demographics, American Society of Anesthesiologists score, admission and discharge dates, presenting pathology, operation type, and discharge destination. Comparative analyses segmented patients based on postdischarge EGS destinations. Multivariable logistic regression identified factors linked to residential/nursing home placement after discharge. Significance was set at P < .05.
RESULTS: Data from all patients in the NELA database (n = 1611) were analyzed. Approximately 1 in 10 patients older than 70 years never returned home. Patients requiring additional support were on average 8.6 years older (P = .008). At older than 80 years, the need for extra social support increased substantially with each increasing year in age, and those older than 85 years were more than twice as likely to require extra support than 80-year-olds (P < .001). Patients who died were 11.4 years older than those discharged without additional support (P < .001).
CONCLUSION: A significant proportion of patients, particularly the elderly, do not return to their usual place of residence and require a higher level of care postemergency surgery. These important social factors need to be considered before operating given that they may have significant quality of life and economic implications.